3SBio acquired China rights for a novel renal failure drug from the Shanghai Institute of Materia Medica; BioChain, a US-China clinical diagnostics company, purchased exclusive China rights to an in-vitro diagnostic test for colorectal cancer from Epigenomics of Germany; Bristol-Myers Squibb in-licensed exclusive China rights to market Coniel, a calcium channel blocker, from Kyowa Hakko Kirin of Japan; Sichuan Kelun Pharma will not complete its previously announced acquisition of a 20% stake in Lijun International Pharma; Charles River Labs purchased BRASS Pte Ltd, a Singapore-based microbiology test lab; China scientists have produced a flu vaccine for the H7N9 bird flu virus, and two China pharmas expressed interest in producing it; WuXi PharmaTech obtained GMP approval from the US FDA for a small molecule API and advanced intermediate CMO facility; Sanofi’s global revenues dropped 6.7% to $11.6 billion in Q3, though China sales were up a modest 5% to $477 million; and Cellular Biomedicine, a US-China stem cell company, is launching a kit in China that isolates stromal cells from adipose tissue.  More details…. Stock Symbols: (F: ECX, OTC: EPGNY) (NYSE: BMY) (TYO: 4151) (SHE: 002422) (HK: 2005) (NYSE: CRL) (NYSE: WX) (NYSE: SNY) (OTCQB: CBMG) Share this with colleagues: // //